Overview

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Status:
Not yet recruiting
Trial end date:
2027-09-24
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company